CompletedPHASE1, PHASE2NCT00078858
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Studying Acquired idiopathic sideroblastic anemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fred Hutchinson Cancer Center
- Principal Investigator
- Brenda SandmaierFred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
- Intervention
- fludarabine phosphate(drug)
- Enrollment
- 37 enrolled
- Eligibility
- All sexes
- Timeline
- 2003
Study locations (10)
- Stanford University Hospitals and Clinics, Stanford, California, United States
- Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States
- Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
- OHSU Knight Cancer Institute, Portland, Oregon, United States
- Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
- Froedtert Memorial Lutheran Hospital, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
- Universitaet Leipzig, Leipzig, Germany
- University of Tuebingen-Germany, Tübingen, Germany
- University of Torino, Torino, Italy
Collaborators
National Heart, Lung, and Blood Institute (NHLBI) · National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00078858 on ClinicalTrials.govOther trials for Acquired idiopathic sideroblastic anemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06270771OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot StudySunnybrook Health Sciences Centre
- RECRUITINGNANCT04869683Biocollection in MyeloDysplastic Syndrome (P-MDS)University Hospital, Brest
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT00392353Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid LeukemiaNational Cancer Institute (NCI)
See all trials for Acquired idiopathic sideroblastic anemia →